Multifocal Motor Neuropathy Plasma

Multifocal Motor Neuropathy Plasma for Autoimmune Neuropathy Research

Multifocal Motor Neuropathy (MMN) Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of multifocal motor neuropathy and processed within one day of collection to preserve labile analytes such as immunoglobulins, complement components, cytokines and metabolites. Plasma is acellular, so it is supplied for soluble-analyte work — ganglioside antibody serology, complement quantification, proteomics and metabolomics — in standard or custom aliquot volumes.

Why MMN Plasma for Autoimmune Neuropathy Research

Multifocal motor neuropathy is an immune-mediated peripheral neuropathy that selectively affects motor nerves. Donors present with slowly progressive, asymmetric limb weakness and characteristic multifocal motor conduction block on nerve conduction studies, with sensory function preserved. The pathogenic effectors are circulating antibodies and complement, both of which reside in the acellular compartment, which makes plasma a mechanistically appropriate specimen for this disease.

• IgM anti-ganglioside antibodies — IgM antibodies against GM1 ganglioside are the best-characterised serological finding in MMN and are detectable in a proportion of donors; other ganglioside reactivities are also described.
• Complement-mediated nodal injury — antibody binding at the node of Ranvier is thought to activate complement and disrupt sodium channel clustering and saltatory conduction, producing the conduction block that defines the condition.
• Motor-selective targeting — the restriction of injury to motor axons distinguishes MMN from sensorimotor immune neuropathies and is a central unresolved question that disease-state material is needed to address.
• Immunoglobulin therapy pharmacology — MMN characteristically responds to intravenous immunoglobulin but not to corticosteroids, making the immunoglobulin and complement compartment the natural focus for pharmacodynamic work.
• Differential diagnosis — MMN is treatable and can be mistaken for motor neuron disease, so specific and sensitive serological discrimination has real clinical value.
• Acellular by design — plasma supports immunoassay, glycoarray serology, complement quantification and mass spectrometry; cellular characterisation requires a cellular product instead.

Donor Stratification Available

• Anti-GM1 antibody status — IgM anti-GM1-positive and antibody-negative donors, subject to documentation
• Anatomical distribution — upper limb-predominant, lower limb-predominant, and multi-limb involvement
• Disease duration and functional severity — early versus long-standing disease, with reported disability measures where captured
• Treatment status — treatment-naive donors, donors on maintenance intravenous or subcutaneous immunoglobulin, and donors sampled at trough versus post-infusion where collected
• Electrophysiological features — documented motor conduction block and preserved sensory conduction, where nerve conduction data are available
• Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity; related immune neuropathy comparator donors also available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed multifocal motor neuropathy donors
• Processed within one day of collection
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request
• Volumes and anticoagulant options reported per lot

De-identified Donor Data

• Verified multifocal motor neuropathy diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Antibody status and immunoglobulin treatment context reported per lot where captured
• Additional MMN-specific metadata available on request

Applications

• IgM anti-GM1 and anti-ganglioside antibody assay development and validation
• Glycoarray and glycolipid antigen serology panel construction
• Complement activation product quantification and pathway analysis
• Differential diagnostic panel development to distinguish MMN from motor neuron disease
• Intravenous immunoglobulin pharmacokinetic and pharmacodynamic marker studies
• Complement inhibitor target engagement readout development
• Neuroaxonal injury and neuroinflammation biomarker discovery
• Plasma proteomic and metabolomic discovery in immune-mediated neuropathy

Other Multifocal Motor Neuropathy Specimen Types

• Multifocal Motor Neuropathy Serum
• Multifocal Motor Neuropathy PBMC
• Multifocal Motor Neuropathy Whole Blood
• CIDP Serum

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Multifocal motor neuropathy plasma is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human plasma page.